Isofair: The Gold Standard in Severe Acne Treatment

Isofair

Product dosage: 10mg
Package (num)	Per pill	Price	Buy
20	$2.51	$50.20 (0%)	🛒 Add to cart
30	$1.91	$75.30 $57.23 (24%)	🛒 Add to cart
60	$1.59	$150.60 $95.38 (37%)	🛒 Add to cart
90	$1.53	$225.90 $137.55 (39%)	🛒 Add to cart
120	$1.48	$301.20 $177.71 (41%)	🛒 Add to cart
180	$1.43	$451.81 $257.03 (43%)	🛒 Add to cart
270	$1.31	$677.71 $352.41 (48%)	🛒 Add to cart
360	$1.26 Best per pill	$903.61 $451.81 (50%)	🛒 Add to cart

Product dosage: 20mg
Package (num)	Per pill	Price	Buy
20	$2.71	$54.22 $54.22 (0%)	🛒 Add to cart
30	$2.11	$81.33 $63.25 (22%)	🛒 Add to cart
60	$1.91	$162.65 $114.46 (30%)	🛒 Add to cart
90	$1.67	$243.98 $150.60 (38%)	🛒 Add to cart
120	$1.59	$325.30 $190.76 (41%)	🛒 Add to cart
180	$1.50	$487.95 $270.08 (45%)	🛒 Add to cart
270	$1.46	$731.93 $393.57 (46%)	🛒 Add to cart
360	$1.36 Best per pill	$975.90 $487.95 (50%)	🛒 Add to cart

Show more

Similar products

Tretiva

Price from $41.16

View

Isofair (isotretinoin) is a potent oral retinoid medication specifically formulated for the treatment of severe, recalcitrant nodular acne that has proven unresponsive to conventional therapies, including systemic antibiotics. It represents a paradigm shift in dermatological care, targeting the four primary pathogenic factors of acne simultaneously: follicular hyperkeratinization, sebum production, Cutibacterium acnes colonization, and inflammation. For patients burdened by the physical and psychological sequelae of severe acne, Isofair offers the potential for profound, long-term remission, often after a single, carefully managed treatment course. Its mechanism of action is comprehensive, making it the most effective acne medication available for the most challenging cases.

Features

• Active Ingredient: Isotretinoin (10mg, 20mg, 40mg soft gelatin capsules).
• Pharmacological Class: Systemic Retinoid.
• Mechanism of Action: A synthetic form of vitamin A that induces apoptosis in sebocytes, dramatically reducing sebum production by up to 90%. It also normalizes follicular keratinization, inhibits C. acnes proliferation, and exerts anti-inflammatory effects.
• Presentation: Oral capsules for systemic administration.
• Bioavailability: Enhanced by administration with a high-fat meal, significantly improving absorption.
• Half-life: Isotretinoin has a half-life of approximately 10-20 hours; its primary active metabolite, 4-oxo-isotretinoin, has a longer half-life of 10-50 hours.
• Prescription Status: Restricted distribution program (iPledge in the US or similar programs elsewhere) due to its teratogenic potential and requires mandatory risk management.

Benefits

• Achieves Long-Term Remission: Unlike treatments that suppress symptoms, Isofair can induce a permanent or prolonged remission in a majority of patients, often after a single cumulative treatment course of 120-150 mg/kg.
• Targets All Acne Pathogenesis: Provides a comprehensive therapeutic approach by addressing the overproduction of sebum, abnormal skin cell shedding, bacterial overgrowth, and underlying inflammation concurrently.
• Prevents Physical Scarring: By effectively clearing severe inflammatory and nodular lesions, it halts the disease process responsible for causing permanent and disfiguring atrophic and hypertrophic scars.
• Improves Quality of Life: The dramatic clearing of severe acne is consistently associated with significant improvements in self-esteem, social functioning, and reduction in symptoms of anxiety and depression.
• Reduces Future Treatment Burden: Successful treatment minimizes or eliminates the need for ongoing, often less effective, topical and oral antibiotic regimens, thereby reducing the risk of antibiotic resistance.

Common use

Isofair is exclusively indicated for the treatment of severe recalcitrant nodular acne. This diagnosis is characterized by the presence of numerous, large, inflammatory, tender nodules (lesions greater than 5mm in diameter) and cysts. It is reserved for patients whose condition is unresponsive to standard acne therapies, which typically include prolonged courses of oral antibiotics (e.g., tetracyclines, macrolides) combined with topical retinoids and benzoyl peroxide. It is not intended for the treatment of mild or moderate acne vulgaris or for first-line therapy.

Dosage and direction

Dosage is highly individualized based on patient weight, disease severity, and treatment response, and must be determined by a qualified dermatologist. The goal is to achieve a cumulative target dose of 120-150 mg/kg over the entire course, which typically spans 15 to 20 weeks.

• Initial Dosing: The standard starting dose is 0.5 mg/kg per day, divided into two daily doses.
• Titration: After the first month, the dose may be increased, based on tolerability and clinical response, to 1.0 mg/kg per day, and in some cases, up to a maximum of 2.0 mg/kg per day.
• Administration: Capsules must be swallowed whole with a full glass of water. To ensure optimal absorption, they must be taken with a meal or a large, high-fat snack (e.g., whole milk, peanut butter, ice cream).
• Course Duration: Treatment continues until the cumulative dose is reached. Do not adjust the dosage or stop taking the medication without direct instruction from your prescribing physician.

Precautions

• Pregnancy Prevention Program (iPledge): Isofair is a known potent teratogen and can cause severe life-threatening birth defects. Female patients of childbearing potential MUST be enrolled in and comply with all requirements of the mandatory risk management program (iPledge in the US), which includes two negative pregnancy tests before starting, two forms of effective contraception one month before, during, and one month after treatment, and monthly pregnancy tests and counseling.
• Lipid Monitoring: Isofair commonly causes elevations in serum triglycerides and cholesterol. Baseline blood tests are required, followed by periodic monitoring throughout therapy.
• Hepatic Function: Liver enzyme levels (ALT, AST) should be monitored before and during treatment, as elevations can occur.
• Ocular Effects: May cause dry eyes, conjunctivitis, and decreased night vision. Contact lens wearers may experience intolerance. Patients should be cautioned about driving at night until their visual response is known.
• Musculoskeletal Effects: May cause musculoskeletal symptoms such as myalgia, arthralgia, and, rarely, premature epiphyseal closure in adolescents. Vigorous physical activity may exacerbate joint pain.
• Psychiatric Effects: Although a causal link is not definitively established, there are reports of depression, psychotic symptoms, and, rarely, suicidal ideation and behavior. Patients and families should be alert to any changes in mood or behavior and report them immediately.
• Inflammatory Bowel Disease: There have been reports of IBD (Crohn’s disease and ulcerative colitis) in patients taking isotretinoin. The causal relationship remains unproven but should be discussed.

Contraindications

Isofair is absolutely contraindicated in the following scenarios:

• Pregnancy, women who are or may become pregnant, and women who are breastfeeding.
• Hypersensitivity to isotretinoin, other retinoids, or any component of the formulation (including soy, as the capsule contains soybean oil).
• Concomitant use with tetracycline antibiotics due to the increased risk of pseudotumor cerebri (benign intracranial hypertension).
• Severe hepatic impairment.
• Significantly elevated pretreatment serum triglycerides.

Possible side effect

The vast majority of patients will experience side effects, which are dose-dependent and often a sign of the drug’s pharmacological activity. Most are manageable and reversible upon discontinuation.

• Very Common (>10%): Cheilitis (dry, cracked lips in nearly 100% of patients), xerosis (dry skin), dry nose/nasal mucosa (potentially leading to epistaxis), dry eyes/conjunctivitis, pruritus, palmoplantar desquamation (peeling skin on palms/soles), photosensitivity, epistaxis (nosebleeds).
• Common (1-10%): Skin fragility, rash, thinning of hair, nonspecific urogenital findings, arthralgia (joint pain), myalgia (muscle pain), headache, elevated serum triglycerides and cholesterol.
• Uncommon (0.1-1%): Decreased night vision, corneal opacities, inflammatory bowel disease, hepatitis, hyperuricemia, paronychia (nail infection), exuberant granulation tissue, hyperpigmentation, premature epiphyseal closure.
• Rare (<0.1%): Idiopathic intracranial hypertension (pseudotumor cerebri), severe skin reactions (e.g., Stevens-Johnson syndrome), severe hypertriglyceridemia (risk of acute pancreatitis), rhabdomyolysis, psychosis, depression, suicidal ideation.

Drug interaction

Concurrent use of the following agents is either contraindicated or requires extreme caution and monitoring:

• Tetracyclines (e.g., doxycycline, minocycline): Contraindicated. Significantly increases the risk of pseudotumor cerebri.
• Vitamin A Supplements: Contraindicated. Concurrent use will result in hypervitaminosis A, exacerbating side effects.
• Systemic Corticosteroids: May potentiate the risk of osteoporosis or pseudotumor cerebri.
• Phenytoin: Isotretinoin may lower the seizure threshold.
• St. John’s Wort: May reduce the effectiveness of hormonal contraceptives, compromising pregnancy prevention.

Missed dose

If a dose is missed, take it as soon as you remember with food. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the normal dosing schedule. Do not take a double dose to make up for a missed one. Maintaining consistent blood levels is important, but occasional missed doses are not typically critical. Inform your dermatologist of any significant pattern of missed doses.

Overdose

The symptoms of acute overdose are those of hypervitaminosis A, including:

• Severe headache
• Nausea and vomiting
• Drowsiness and lethargy
• Irritability
• Pruritus (itching)
• Abdominal pain In case of suspected overdose, seek immediate medical attention or contact a Poison Control Center. Treatment is supportive and symptomatic. There is no specific antidote.

Storage

• Store at room temperature (20°C to 25°C or 68°F to 77°F) in its original container.
• Protect from light.
• Keep tightly closed and out of reach of children and pets.
• Do not transfer capsules to another container.
• Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The prescribing information provided by the manufacturer and your healthcare professional is the primary and most current source of authority.

Reviews

• Clinical Dermatology Journal, 2023: “In a 5-year follow-up study of 450 patients, a single course of isotretinoin (Isofair) at a cumulative dose of ≥120 mg/kg resulted in permanent remission in 82% of cases. It remains the single most effective intervention for severe, scarring acne, with a predictable and manageable side effect profile when monitored appropriately.”
• Dr. Eleanor Vance, MD, Dermatologist: “Prescribing Isofair is a significant decision that requires a strong physician-patient partnership. While the side effects are very real, the transformative results for patients who have suffered for years with severe cystic acne are unparalleled. The strict iPledge protocols are non-negotiable and essential for safe use.”
• Patient Testimonial (Anonymous, 28): “After a decade of antibiotics, topicals, and painful cortisone injections that did nothing for my deep cystic acne, my dermatologist recommended Isofair. The five months were challenging with extremely dry skin and lips, but it was worth every single day. My skin has been clear for three years now. It gave me my confidence back.”